Sunshine Biopharma (SBFM) Projected to Post Earnings on Tuesday

Sunshine Biopharma (NASDAQ:SBFM) is expected to issue its results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($1.20) per share and revenue of $8.70 million for the quarter.

Sunshine Biopharma (NASDAQ:SBFM) last announced its earnings results on Wednesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.60) by $1.35. Sunshine Biopharma had a negative net margin of 18.45% and a negative return on equity of 27.75%. The company had revenue of $8.09 million during the quarter, compared to analyst estimates of $9.20 million.

Sunshine Biopharma Stock Up 15.8%

SBFM traded up $0.18 during trading on Tuesday, hitting $1.35. The company’s stock had a trading volume of 1,580,052 shares, compared to its average volume of 709,763. Sunshine Biopharma has a one year low of $1.10 and a one year high of $24.30. The firm has a market cap of $677,500.00, a PE ratio of -0.11 and a beta of 1.17. The business’s 50 day simple moving average is $2.13 and its 200-day simple moving average is $7.56.

Institutional Investors Weigh In On Sunshine Biopharma

A number of institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC lifted its position in shares of Sunshine Biopharma by 23.1% in the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock valued at $116,000 after acquiring an additional 14,656 shares in the last quarter. Two Sigma Investments LP bought a new stake in Sunshine Biopharma during the 3rd quarter valued at approximately $32,000. Finally, Virtu Financial LLC purchased a new position in Sunshine Biopharma in the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 41.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Zacks Research raised Sunshine Biopharma to a “hold” rating in a report on Wednesday, May 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Sunshine Biopharma in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Sunshine Biopharma presently has a consensus rating of “Hold” and an average price target of $70.00.

About Sunshine Biopharma

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.